首页> 外文期刊>Pulmonary Circulation >Emerging Roles for Histone Deacetylases in Pulmonary Hypertension and Right Ventricular Remodeling (2013 Grover Conference series):
【24h】

Emerging Roles for Histone Deacetylases in Pulmonary Hypertension and Right Ventricular Remodeling (2013 Grover Conference series):

机译:组蛋白脱乙酰基酶在肺动脉高压和右心室重构中的新兴作用(2013年格罗弗会议系列):

获取原文
获取外文期刊封面目录资料

摘要

Reversible lysine acetylation has emerged as a critical mechanism for controlling the function of nucleosomal histones as well as diverse nonhistone proteins. Acetyl groups are conjugated to lysine residues in proteins by histone acetyltransferases and removed by histone deacetylases (HDACs), which are also commonly referred to as lysine deacetylases. Over the past decade, many studies have shown that HDACs play crucial roles in the control of left ventricular (LV) cardiac remodeling in response to stress. Small molecule HDAC inhibitors block pathological hypertrophy and fibrosis and improve cardiac function in various preclinical models of LV failure. Only recently have HDACs been studied in the context of right ventricular (RV) failure, which commonly occurs in patients who experience pulmonary hypertension (PH). Here, we review recent findings with HDAC inhibitors in models of PH and RV remodeling, propose next steps for this newly uncovered area of research, and highlight potential for isoform-selective HDAC inhibitors for the treatment of PH and RV failure.
机译:可逆的赖氨酸乙酰化已成为控制核小体组蛋白以及各种非组蛋白蛋白功能的关键机制。乙酰基通过组蛋白乙酰基转移酶与蛋白质中的赖氨酸残基缀合,并通过组蛋白脱乙酰基酶(HDAC)(通常也称为赖氨酸脱乙酰基酶)去除。在过去的十年中,许多研究表明,HDAC在响应压力的控制左心室(LV)心脏重塑中起关键作用。小分子HDAC抑制剂可在各种LV衰竭的临床前模型中阻止病理性肥大和纤维化并改善心脏功能。直到最近,才在右心室(RV)衰竭的背景下研究HDAC,这通常发生在患有肺动脉高压(PH)的患者中。在这里,我们回顾了在PH和RV重塑模型中使用HDAC抑制剂的最新发现,为这一新发现的研究领域提出了下一步的建议,并强调了同种型选择性HDAC抑制剂在治疗PH和RV衰竭方面的潜力。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号